CC Chemours Co

FY2025 10-K
Filed: Feb 24, 2026
Health Care
Chemicals & Allied ProductsSEC EDGAR

Chemours Co (CC) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business: global provider of performance chemicals serving diverse industries via three segments—Thermal & Specialized Solutions, Titanium Technologies, Advanced Performance Materials
  • New strategy "Pathway to Thrive" launched in 2024 focusing on operational excellence, growth in data center cooling, next-gen refrigerants, and semiconductor fabrication
+3 more insights

Management Discussion & Analysis

  • Revenue $5.758B, down 2% YoY; Thermal & Specialized Solutions up $236M (13%) to $2.1B, Titanium Technologies down $143M (6%) to $2.4B, Advanced Performance Materials down $63M (5%) to $1.3B
  • Profitability: Thermal & Specialized Solutions Adj. EBITDA margin 32% vs 31%, Titanium Technologies margin 6% vs 12%, Advanced Performance Materials margin 9% vs 12%
+3 more insights

Risk Factors

  • Litigation risk: $270 million settlement charge with State of New Jersey for environmental litigation in 2025
  • Geopolitical risk: Sale of Taiwan Titanium site for $360 million pending local regulatory and environmental approvals, mid-2026
+3 more insights

Financial Summary
XBRL

Revenue

$5.8B

Net Income

-$386M

Gross Margin

15.5%

Net Margin

-6.6%

ROE

-154.4%

Total Assets

$7.4B

EPS (Diluted)

$-2.57

Operating Cash Flow

$264M

Source: XBRL data from Chemours Co FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Chemours Co

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available